Celltrion Submits Phase 3 Clinical Trial Application for European Interchangeability of Uplima
[Asia Economy Reporter Minji Lee] Celltrion announced on the 23rd that it has submitted a clinical trial application for the Phase 3 interchangeability study of Uplyma to the Estonian Medicines Agency.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "Hancom Breaks Away from Its 36-Year Mission and Formula for Success" (Comprehensive)
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "In addition to the marketing authorization for all indications approved for the original product, by additionally proving interchangeability, we expect to increase market share in the large-scale US market."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
